No Data
No Data
No Data
No Data
No Data
Zhitong Hong Kong Shareholders' Rights Disclosure | April 24
Disclosure of Hong Kong Stock Shareholders' Rights | April 24
Zhitong Finance20:05 ET
China Biopharmaceuticals (01177.HK) received 2 million additional shares from Chairman Xie Qirun
Gelonghui, April 24 | According to the latest equity disclosure data of the Stock Exchange, on April 23, 2024, China Biopharmaceutical (01177.HK) was granted an increase of 2 million shares at an average price of HK$2.5891 per share on the market, involving approximately HK$5.1782 million. After the increase in holdings, Xie Qirun's latest shareholding was 6 million shares, and the shareholding ratio increased from 0.02% to 0.03%.
Gelonghui Finance18:34 ET
China Biopharmaceuticals (01177.HK) gains 5 million shares by Executive Director Xie Chengrun
Gelonghui, April 23 | According to the latest equity disclosure data of the Stock Exchange, on April 19, 2024, China Biopharmaceutical (01177.HK) was granted an increase of 5 million shares by Executive Director Xie Chengrun on the market at an average price of HK$239 per share, involving approximately HK$116.19,500. After the increase in holdings, Tse Chengyun's latest shareholding was 4,055,000,000 shares, and the shareholding ratio increased from 21.54% to 21.57%.
Gelonghui FinanceApr 22 18:48 ET
Changes in Hong Kong stocks | Zhongsheng Pharmaceuticals (01177) is now up more than 5%, key registration studies on the innovative drug lovaxitinib tablets have reached the main end
Zhongsheng Pharmaceutical (01177) is now up more than 5%. As of press release, it has risen 4.7% to HK$2.45, with a turnover of HK$27.146,500.
Zhitong FinanceApr 21 21:33 ET
Zhitong Hong Kong Shareholders' Rights Disclosure | April 22
Disclosure of Hong Kong Stock Shareholders' Rights | April 22
Zhitong FinanceApr 21 20:05 ET
China Biopharmaceuticals (01177.HK) received 2.5 million shares from Chairman Xie Qirun
Gelonghui, April 22丨According to the latest equity disclosure data of the Stock Exchange, on April 19, 2024, China Biopharmaceutical (01177.HK) was granted an increase of 2.5 million shares at an average price of HK$2.3223 per share on the market, involving approximately HK$5.8058 million. After the increase in holdings, Xie Qirun's latest shareholding was 4 million shares, and the shareholding ratio increased from 0.01% to 0.02%.
Gelonghui FinanceApr 21 18:29 ET
No Data
No Data